William Blair analyst Brandon Vazquez has maintained their bullish stance on DXCM stock, giving a Buy rating today.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Vazquez has given his Buy rating due to a combination of factors, primarily focusing on the recent improvements in Dexcom’s sensor reliability. The analysis of the September MAUDE filings indicates a decline in Dexcom’s G7 filings, suggesting that previous reliability issues are being addressed effectively. This trend, coupled with the context of an increasing user base, shows a decreasing rate of filings per user, which is a positive indicator for the company’s performance.
Furthermore, preliminary survey results suggest that the churn rate between Dexcom and its competitor Abbott is not significantly different, indicating that market dynamics might be more influenced by external perceptions rather than actual product performance. Vazquez also anticipates that Dexcom’s third-quarter results will be crucial in reinforcing investor confidence in the company’s management and execution. With the potential for a positive earnings surprise and current share valuations, Vazquez maintains an optimistic outlook on Dexcom’s stock performance.
According to TipRanks, Vazquez is an analyst with an average return of -2.5% and a 33.87% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as PROCEPT BioRobotics, Align Tech, and DENTSPLY SIRONA.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $105.00 price target.